What Is CJC-1295?
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, usually discussed in relation to the first 29 amino acids of GHRH, also known as GRF(1-29). It belongs to a different GH-axis category than GHRP compounds such as Ipamorelin. CJC-1295 is studied for GHRH receptor activity, while Ipamorelin is studied for growth hormone secretagogue receptor activity.
That distinction is central to understanding why CJC-1295 appears so often in growth hormone research discussions. It is not growth hormone itself; it is a GHRH analogue used to explore signalling upstream of GH release.
CJC-1295 With DAC vs CJC-1295 Without DAC
The phrase “CJC-1295” can cause confusion because suppliers and research discussions may use it for more than one related material. The most important catalogue distinction is whether the product includes DAC.
| Listing term | Research meaning | Key comparison point |
|---|---|---|
| CJC-1295 with DAC | Long-acting GHRH analogue with a Drug Affinity Complex. | DAC supports albumin binding and extended exposure in research models. |
| CJC-1295 without DAC | Often listed as MOD GRF 1-29. | Shorter-acting GHRH analogue used where researchers want a different exposure profile. |
The DAC version is the form most closely associated with the original long-acting CJC-1295 literature. A clinical pharmacology paper reported sustained GH and IGF-1 responses after CJC-1295 exposure and described an estimated half-life in the 5.8-8.1 day range for the long-acting compound. That does not mean every listing described as “CJC” has the same behaviour, which is why the product title matters.
Why CJC-1295 Is Studied Alongside Ipamorelin
CJC-1295 and Ipamorelin are frequently discussed together because they relate to different parts of the same broad GH-axis research area. CJC-1295 is a GHRH analogue; Ipamorelin is a GHSR agonist. Researchers comparing both categories can separate GHRH receptor signalling from growth hormone secretagogue receptor signalling.
This is also why the phrase “CJC-1295 and Ipamorelin stack” appears in search behaviour. For PeptidesNextDay content, the useful point is not protocol advice. The useful point is terminology: the two compounds are mechanistically different, and any comparison should start with receptor class, DAC status, quantity, and intended research readout.
Catalogue Comparison Checklist
PeptidesNextDay lists both DAC and no-DAC CJC-1295 formats. Customers comparing product pages should check the full product title before ordering:
- CJC-1295 MOD GRF 1-29 / without DAC 2mg
- CJC-1295 MOD GRF 1-29 / without DAC 5mg
- CJC-1295 with DAC 2mg
- CJC-1295 with DAC 5mg
Research Use Notice
CJC-1295 products sold through PeptidesNextDay are specialist peptide products and supporting catalogue items. They are not medicines or supplements and are not approved for human or veterinary administration. This article is provided for product terminology, catalogue comparison, and research context only.